Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

A Drug Development Update from Obio Pharma

publication date: Feb 23, 2009

Obio Pharmaceutical Holdings Ltd. has issued a release detailing the progress of its current crop of drug candidates. The company, which claims a focus on diabetes and influenza, reports that it has six drugs in development, two of them patented. The company plans to develop these drugs and then partner them with larger companies to bring them to market. Obio is headquartered in Hong Kong, but its research facilities are in Beijing. It also outsources some of its R&D work to outside groups. More details...



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital